由于2025年可能减少收入,UBS降级了联合保健公司的价格目标。 UBS downgrades UnitedHealth's price target due to potential earnings reduction for 2025.

6月25日,UBS维持了对联合保健集团(UNH)的买入评级,但将其价格目标从400美元降至385美元。 On June 25, UBS maintained its Buy rating on UnitedHealth Group (UNH) but lowered its price target to $385 from $400. 这项调整是根据该公司的首席执行官在年度会议上的意见作出的,建议2025年收入指南可能减少,与7月29日的 " 问题2 " 报告一起公布。 This adjustment follows the company's CEO's comments at the annual meeting, suggesting a potential reduction in 2025 earnings guidance to be released with the Q2 report on July 29. 瑞银现在预计每股收益约为 20 美元，低于 22.50 美元，并且 Medicare Advantage 和 Optum Health 利润率的利润预测下调。 UBS now expects earnings around $20 per share, down from $22.50, and decreased profit forecasts for Medicare Advantage and Optum Health margins.